Synthesis and Evaluation of Polymer-Antibody Hybrid with Pharmacologically Active Domains

点击翻译按钮获取中文摘要

"Missile drug" is a technique to deliver drugs selectively to the organs or tissues where a medical treatment is needed, and as a result, to inhibit the side effects of drugs. One of the most promising types of missile drug is a conjugate of antibody with drugs via intermediate carrier polymer. In a conjugate of this type, intermediate carrier polymer plays a role in connecting as much drug as possible to antibody by minimum connecting points with antibody, and consequently a highly active conjugate with minimum decrease in antigen binding capacity of antibody is obtained. We consider that molecular design of intermediate carrier polymer is critically important to obtain the best quality of this type of missile drug. From this point of view, poly(ethylene glycol)-poly(aspartic acid) block copolymer is used as an intermediate carrier polymer. Poly(ethylene glycol) chain is considered to decrease antigenicity af missile drug, and to increase water- solubility and stability in blood stream. Poly(aspartic acid) chain carriers anti-cancer drug (adriamycin) with covalent bond and is expected to be degraded after the uptake by target cells. In this research, synthesis of a novel conjugate of anti-cancer drug adriamycin, poly(ethylene glycol)-block-poly(aspartic acid), and immunoglobulin G is conducted. Poly(ethylene glycol)-block-poly(aspartic acid), binding adriamycin on the poly( aspartic acid) chain, showed an excellent water-solubility despite the introduction of a large amount of strongly hydrophobic adriamycin, and was found to form a micellar structure in aqueous salution. Efficient coupling between poly(ethylene glycol)-block-poly( aspartic acid) binding adriamycin and immunaglobulin G was achieved via disulfide linkages.